Objectives: This study assessed the utility of Cameron's Illness Risk Representation (IRR) framework in understanding how women interpret their breast cancer risk after receiving a clinically derived estimate.
Design: Secondary qualitative analysis of two studies within the BC-Predict trial, using semi-structured telephone interviews with women aged 47-74 who received breast cancer risk estimates via population screening.
Methods: Forty-eight women were informed of their 10-year breast cancer risk (low (<1.5% risk), average (1.5-4.99%), above-average (moderate; 5-7.99%) and high (≥8%)). Moderate- and high-risk women were eligible for enhanced preventive management. Women were interviewed about their risk, with data analysed using a thematic framework approach.
Results: Causal representations of breast cancer were often incomplete, with women primarily relying on family history and health-related behaviours to understand their risk. This reliance shaped pre-existing expectations and led to uncertainty about unfamiliar risk factors. As women aged, concerns about breast cancer susceptibility became more prominent. Emotional reactions to risk communication, along with the physical implications of risk management strategies, were also considered. Women were knowledgeable about early detection and prevention strategies, showing agency in reducing risk and preventing aggressive cancers.
Conclusions: The IRR framework largely explained women's breast cancer risk appraisals but adaptations could enhance its applicability. The identity construct could be redefined and combined with the causal construct. The framework should also consider the extent to which pre-existing appraisals change after receiving a clinical-derived risk estimate. Healthcare professionals should assess women's knowledge before communicating personal risk estimates to reduce doubt and the impact of unfamiliar information.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/bjhp.12792 | DOI Listing |
FASEB J
March 2025
Department of Oncology, The Central Hospital of Yongzhou, Yongzhou, Hunan, China.
The ribophorin family, including RPN1, has been associated with tumor progression, but its specific role in pan-cancer dynamics remains unclear. Using data from TCGA, GTEx, and Ualcan databases, we investigated the relationship of RPN1 with prognosis, genomic alterations, and epigenetic modifications across various cancers. Differential analysis revealed elevated RPN1 expression in multiple cancer types, indicating a potential prognostic value.
View Article and Find Full Text PDFCancer Med
March 2025
Department of Neurosurgery, Duke University Medical Center, Durham, North Carolina, USA.
Introduction: Distress is common among cancer patients, especially those undergoing surgery. However, no study has systematically analyzed distress trends in this population. The purpose of this study was to systematically review perioperative rates of distress, as well as differences across cancer types, in cancer patients undergoing surgical intervention.
View Article and Find Full Text PDFFASEB J
March 2025
Cancer Center, The First Affiliated Hospital of Jilin University, Changchun, Jilin, China.
Breast cancer (BC) is one of the most common malignant tumors among women, accounting for 24.5% of all cancer cases and leading to 15.5% of cancer-related mortality.
View Article and Find Full Text PDFJ Biomol Struct Dyn
March 2025
Applied Organic Chemistry Department, National Research Center, Dokki, Egypt.
The discovery of novel, selective inhibitors targeting CDK2 and PIM1 kinases, which regulate cell survival, proliferation, and treatment resistance, is crucial for advancing cancer therapy. This study reports the design, synthesis, and biological evaluation of three novel pyrazolo[3,4-]pyridine derivatives (), confirmed spectral analyses. These compounds were assessed for anti-cancer activity against breast, colon, liver, and cervical cancers using the MTT assay.
View Article and Find Full Text PDFAdv Healthc Mater
March 2025
Department of Ultrasound, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361000, P. R. China.
The abnormal tumor mechanical microenvironment due to specific cancer-associated fibroblasts (CAFs) subset and low tumor immunogenicity caused by inefficient conversion of active chemotherapeutic agents are two key obstacles that impede patients with desmoplastic tumors from achieving stable and complete immune responses. Herein, it is demonstrated that FAP-αCAFs-induced stromal stiffness accelerated tumor progression by precluding cytotoxic T lymphocytes. Subsequently, a cascade-responsive nanoprodrug capable of re-educating FAP-αCAFs and amplifying tumor immunogenicity for potentiated cancer mechanoimmunotherapy is ingeniously designed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!